Table 1. Demographic and Disease Characteristics in Randomised Phase 3 Study 1007 (Full Analysis Population) Characteristics Crizotinib Chemotherapy N=173 N=174 Sex, n (%) Male 75 (43) 78 (45) 98 (57) 96 (55) Female Age n (%) Median (range) 51 (22-81) 49 (24-85) 146 (84) 151 (87) <65 27 (16) 23 (13) >65 years Race, n (%) White 90 (52) 91 (52) 2 (1) 3 (2) 79 (46) 78 (45) 2 (1) 2 (1) Other Smoking Status, n (%) Never smoked 108 (62) 111 (64) 59 (34) 54 (31) Ex-smoker 5 (3) 9 (5) Current smoker 1 (<1) 0 Not reported Disease Stage, n (%) Locally advanced 7 (4) 16 (9) 165 (95) 158 (91) Metastatic 1 (<1) 0 Not reported Histological Classification, n (%) Adenocarcinoma 163 (94) 160 (92) 0 3 (2) Squamous cell carcinoma 1 (<1) 1 (<1) Large cell carcinoma 4 (2) 3 (2) Adenosquamous carcinoma 4 (2) 7 (4) Other 1 (<1) 0 Not reported Brain Metastases, n (%) Present 60 (35) 60 (34) 113 (65) 114 (66) Absent Prior EGFR TKI Therapy, n (%) Yes 20 (12) 21 (12) 153 (88) 153 (88) No ECOG PS, n (%) 0 72 (42) 65 (37) 84 (49) 95 (55) 1 16 (9) 14 (8) 2 1 (<1) 0 Not reported
Table 1. Demographic and Disease Characteristics in Randomised Phase 3 Study 1007 (Full Analysis Population) Characteristics Crizotinib N=173 Chemotherapy N=174 Sex, n (%) Male Female 75 (43) 98 (57) 78 (45) 96 (55) Age n (%) Median (range) <65 >65 years 51 (22-81) 146 (84) 27 (16) 49 (24-85) 151 (87) 23 (13) Race, n (%) White Other 90 (52) 2 (1) 79 (46) 2 (1) 91 (52) 3 (2) 78 (45) 2 (1) Smoking Status, n (%) Never smoked Ex-smoker Current smoker Not reported 108 (62) 59 (34) 5 (3) 1 (<1) 111 (64) 54 (31) 9 (5) 0 Disease Stage, n (%) Locally advanced Metastatic Not reported 7 (4) 165 (95) 1 (<1) 16 (9) 158 (91) 0 Histological Classification, n (%) Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Adenosquamous carcinoma Other Not reported 163 (94) 0 1 (<1) 4 (2) 4 (2) 1 (<1) 160 (92) 3 (2) 1 (<1) 3 (2) 7 (4) 0 Brain Metastases, n (%) Present Absent 60 (35) 113 (65) 60 (34) 114 (66) Prior EGFR TKI Therapy, n (%) Yes No 20 (12) 153 (88) 21 (12) 153 (88) ECOG PS, n (%) 0 1 2 Not reported 72 (42) 84 (49) 16 (9) 1 (<1) 65 (37) 95 (55) 14 (8) 0
auspar-crizotinib-130620-pi.docx